A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.

A device for delivering a predetermined amount of a substance within at least one body cavity of a subject, where the predetermined amount is at an effective amount for treatment of obesity or binge eating disorder. The device includes (a) A volume to contain the predetermined amount of the substance. (b) A delivery end placeable in proximity to the body cavity. The delivery end is in fluid communication with the volume and comprises at least one orifice. (c) A valve mechanically connected to the volume, with at least two configurations: (i) an active configuration configured to deliver the predetermined amount of the substance; and, (ii) an inactive configuration, in which the valve prevents delivery of the predetermined amount of the substance. (d) A fluid tight chamber configured to contain a predetermined volume of pressurized gas at a predetermined pressure.

A therapeutic device for treating one or more conditions associated with a user's nasal cavities, sinuses, and/or ear canals includes a housing having an opening, an acoustic vibrator within the housing that is operable to provide an acoustic vibration to the user, a fan within the housing that is operable to provide a pressure to the user and a power supply that provides power to the acoustic vibrator and the fan. A mask is connected to the housing at the opening and includes a nasal interface appliable around the nose of the user, a nasal chamber in which the user's nostrils are located and an aperture through which the fan delivers the pressure.

A delivery device for and method of modulating a condition relating to social cognition and/or behaviour in a human subject using oxytocin, non-peptide agonists thereof and/or antagonists thereof, comprising: providing a nosepiece to a first nasal cavity of the subject; and providing a supply unit for administering less than 24 IU of oxytocin, non-peptide agonists thereof and/or antagonists thereof through the nosepiece to an upper region posterior of the nasal valve which is innervated by the trigeminal nerve.

A nasal delivery device for and method of delivering substance to a nasal airway of a subject, the delivery device comprising: a nosepiece (117) for fitting to a nasal cavity of a subject, a mouthpiece (119) into which the subject in use exhales; a delivery unit, which comprises an actuation part which is manually displaceable to actuate the delivery unit to deliver substance from the nosepiece; and a valve assembly (127) which is fluidly connected to the nosepiece and the mouthpiece, wherein the valve assembly comprises a body element (128) and a valve element (131) which is movably disposed to the body element between closed and open configurations by manual displacement of the actuation part of the delivery unit to provide for an air flow through the nosepiece simultaneously with delivery of substance.

A nosepiece for delivering substance to a nasal cavity of a subject, the nosepiece comprising a body part which comprises a base portion which defines a flow passage therethrough, and a projection at a distal end of the base portion which at least in part provides a tip of the nosepiece and confers a rigidity in the sagittal direction, which enables the tip to open fleshy tissue at an upper region of the nasal valve and thereby expand an open area of the nasal valve, and a flexibility in a lateral direction, orthogonal to the sagittal plane, which facilitates insertion of the tip into the nasal valve.

A therapeutic device for treating one or more conditions associated with a user's nasal cavities, sinuses, and/or ear canals includes a vibration generator having an acoustic device operable to provide a sound; a seal configured to cover a nose, but not a mouth, of the user to form an air-tight chamber around the nose of the user; the vibration generator disposed in a housing connected to the seal; and a stand extending from the housing and including a ball bearing and a seat on which the ball bearing may rest, the stand including a hollow member and an orifice, the orifice disposed in the seat. The vibration generator provides the sound directly to the nose of the user. A positive pressure is created in the air-tight chamber when the user exhales, the positive pressure generating a lift force to lift the ball bearing from the seat.

A nasal delivery device for and a method of delivering substance to a nasal airway of a subject, the nasal delivery device including a mouthpiece (519) through which the subject in use exhales to cause closure of the oropharyngeal velum of the subject; a nosepiece (517) for fitting to a nostril of a subject, the nosepiece including a nozzle (549) through which the substance is in use delivered to the nasal airway; and a manually-actuatable substance supply unit (520) for delivering substance through the nozzle of the nosepiece.

A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.

A delivery device for and method of modulating a condition relating to sodal cognition and/or behaviour in a human subject using oxytocin, non-peptide agonists thereof and/or antagonists thereof, comprising: providing a nosepiece to a first nasal cavity of the subject; and providing a supply unit for administering less than 24 IU of oxytocin, non-peptide agonists thereof and/or antagonists thereof through the nosepiece to an upper region posterior of the nasal valve which is innervated by the trigeminal nerve.